GleamWall
中文EN

PASG Passage BIO, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1787297 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY26.9%
TTM EPS YoY27.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-212.3%
ROA-69.7%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets99.8%
Debt / equity0.00x
Current ratio1.00x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.99x
Accruals ratio-0.9%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$23.28M$40.18M
SG&A expense$19.88M$24.99M
Operating income-$49.30M-$70.40M
Income tax$0$0
Net income-$45.52M-$64.77M
EBITDA-$48.57M-$67.32M
EPS (basic)-14.35-21.04
EPS (diluted)-14.35-21.04
Weighted avg. shares (diluted)3.17M3.08M
Balance sheet
Cash & equivalents$46.30M$37.57M
Short-term investments$0$39.18M
Current assets$47.76M$78.81M
PP&E, net$4.11M$9.33M
Total assets$62.28M$102.41M
Current liabilities$23.08M$19.36M
Total liabilities$43.53M$41.15M
Shareholders' equity$18.75M$61.26M
Shares outstanding3.18M3.16M
Cash flow statement
Operating cash flow-$31.51M-$47.96M
Capital expenditure—$34,000
Free cash flow—-$47.99M
Investing cash flow$40.22M$54.95M
Financing cash flow$23,000$8.87M
Depreciation & amortization$728,000$3.08M
Stock-based compensation$3.00M$5.82M

Free plan shows the latest 2 periods; Pro shows all 7 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.